Immune & Longevity Peptides

Thymosin Alpha 1 (Tα1, thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymic extract, by Allan Goldstein and colleagues in the 1970s. It represents one of the few immune-modulating peptides with genuine clinical evidence: thymalfasin (Zadaxin) is approved in over 35 countries for chronic hepatitis B, hepatitis C (as adjunct to interferon), and as an immunorestorative agent in certain immunocompromised states, though it does not have FDA approval in the United States (PMID 19392576). Understanding Tα1's biology and evidence base is important for clinicians encountering patient interest in its use for immune optimization (PMID 19392576).

Tα1 is naturally produced by thymic epithelial cells and secreted into the bloodstream, where it acts as a systemic immune modulator. Its primary effects are on T-cell development, differentiation, and activation. Mechanistically, Tα1 binds toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells and stimulates type 1 interferon production, a critical first-line antiviral defense (PMID 17804687). It also primes dendritic cells for T helper type 1 responses and promotes interferon-dependent antiviral immunity (PMID 17804687). In a mouse model of sepsis, thymosin alpha 1 decreased the proportion of CD4+CD25+Foxp3+ regulatory T cells by promoting their apoptosis and improved survival, suggesting Treg modulation as one component of its immunomodulatory action; corresponding human data are limited and in vitro work in cancer patients has shown the opposite direction (PMID 21622217).

Clinical evidence beyond the approved viral hepatitis indications is preliminary but encouraging. In the multicenter randomized ETASS trial in severe sepsis, 28-day all-cause mortality was 26.0% with thymosin alpha 1 versus 35.0% in controls (log-rank P = 0.049; nonstratified P = 0.062) and monocyte HLA-DR expression improved more on Talpha1, suggesting partial restoration of immunocompetence (PMID 23327199). However, the larger phase 3 TESTS trial (1,106 adults with sepsis) found no clear reduction in 28-day mortality with thymosin alpha 1 (PMID 39814420). Thymosin alpha-1 was widely used in COVID-19, but a meta-analysis of nine studies including more than 5,000 patients found no statistically significant effect on mortality (PMID 36527881). Clinical reports of thymosin alpha-1 in cancer care are dominated by retrospective observational studies and case reports, usually as an adjunct to chemotherapy, radiotherapy, targeted therapy or checkpoint inhibitors, rather than by randomized efficacy trials (PMID 42797537).

In hepatitis B trials, and where thymalfasin is approved outside the US, the regimen studied was 1.6 mg subcutaneously twice weekly for 6 months (PMID 10607256).)). Thymosin alpha-1 is generally described as well tolerated, but much of its clinical literature consists of observational studies and case reports with inconsistent safety reporting, so uncommon risks cannot be excluded (PMID 42797537). Its primary limitation is the lack of FDA approval for any indication in the United States, requiring clinicians to rely on compounded preparations and to clearly communicate this status to patients.